<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312690</article-id>
      <article-id pub-id-type="pmc">4540524</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153768</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary cutaneous follicle center lymphoma simulating basal-cell
carcinoma on the nasal ala<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Wanczinsnki</surname>
            <given-names>Mariana Isis</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Cl&#xF3;vis Antonio Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Trevisan</surname>
            <given-names>Fl&#xE1;via</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cunha</surname>
            <given-names>Paulo Rowilson</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grohs</surname>
            <given-names>Luz Marina Hannah</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Faculdade de Medicina de Jundia&#xED; (FMJ) - Jundia&#xED; (SP),
Brazil.</aff>
      <aff id="aff02"><label>2</label>Universidade Federal do Paran&#xE1; (UFPR) - Curitiba (PR),
Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Fl&#xE1;via Trevisan, Rua Francisco Telles, 250, Vila
Arens, 13202-550 Jundia&#xED; - SP, Brazil. E-mail:
<email>flaviatrevisan1@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>111</fpage>
      <lpage>114</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Primary cutaneous B-cell lymphomas (PCBCLs) constitute 25% of all primary cutaneous
lymphomas. They present in the skin with no evidence of systemic or extracutaneous
disease at the time of diagnosis, after adequate staging. Primary cutaneous B-cell
lymphomas differ significantly from their nodal counterparts in relation to both
clinical behavior and prognosis. The distinction between primary and secondary B-cell
lymphomas is essential for defining prognosis/course of action. Such distinction is
also very difficult to make, since primary and secondary B-cell lymphomas are
clinically and histologically indistinguishable. We report the case of a patient with
primary cutaneous follicle center lymphoma who underwent surgical excision.</p>
      </abstract>
      <kwd-group>
        <kwd>Carcinoma, basal cell</kwd>
        <kwd>Lymphoma, B-cell</kwd>
        <kwd>Lymphoma, B-cell, marginal zone</kwd>
        <kwd>Lymphoma, follicular</kwd>
        <kwd>Lymphoma, non-Hodgkin</kwd>
        <kwd>Precursor cell lymphoblastic leukemia-lymphoma</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The lymphomas are a group of neoplasms arising from the lymphoreticular system. They are
divided into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin lymphomas (NHL).
The latter may be nodal (when primarily involving the lymph nodes) or
extranodal.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> About 30% of NHL
involve extranodal tissues. The skin is the second most affected organ (after the
gastrointestinal tract), comprising approximately 18% of these lymphomas.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>Based on their cellular origin and according to the expressed monoclonal antibodies,
lymphomas can be divided into T- or B-cell lymphomas.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> The expression
of CD3, CD4, CD8, CD43 or CD45 confirms their T-cell character. The expression of CD20,
in particular, but also of CD79, CD5 and CD10 confirms their B-cell character.<sup><xref rid="r03" ref-type="bibr">3</xref></sup> Cutaneous B-cell lymphomas (CBCL) are
less frequent than cutaneous T-cell lymphomas, representing about 25% of all cutaneous
lymphomas. It shows a slight pREFERENCES for males and an increased incidence with
age.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>CBCL can be primary or secondary. Primary CBCL have a more indolent natural history than
secondary CBCL and a good prognosis. They are characterized by having only cutaneous
presentation, with no evidence of extracutaneous lesion after adequate staging. They
have an identical morphological appearance but different clinical behaviors.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>In 2005, the World Health Organization (WHO) and the European Organization for Research
and Treatment of Cancer (EORTC) proposed a classification for primary cutaneous
lymphomas. CBCL were divided into marginal zone, follicle center, diffuse large B-cell,
leg type and intravascular large B-cell lymphoma (<xref ref-type="table" rid="t01">Chart
1</xref>).<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>CHART 1</label>
        <caption>
          <p>Classification of cutaneous lymphomas (WHO/EORTC, 2005)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Neoplasms of mature T and NK cells</td>
              <td align="left" rowspan="1" colspan="1">Mycosis fungoides</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Variants of mycosis fungoides</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Subtype of mycosis fungoides</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Sezary syndrome</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">CD30-Positive T-Cell Lymphoproliferative Disorders</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Subcutaneous panniculitis-like T-cell lymphoma</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Peripheral t-cell lymphoma, non specific</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Extranodal NK/T-cell lymphoma, nasal type</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Adult T-cell leukemia /lymphoma</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Extracutaneous lymphomas, usually with skin involvement</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">B-cells neoplasms</td>
              <td align="left" rowspan="1" colspan="1">Cutaneous marginal zone B-cell lymphoma (MALT type)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Primary cutaneous follicle center lymphoma</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;Follicular</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;Follicular and diffuse</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;Diffuse</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Cutaneous large B-cell lymphoma</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;Leg type</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;Others</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Intravascular large B-cell lymphoma</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Immature hematopoietic malignancies</td>
              <td align="left" rowspan="1" colspan="1">Blastic NK cell lymphoma / CD4+/CD56+ hematodermic
neoplasia</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Lymphoblastic precursor lymphoma/leukemia</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;T-cells</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;B-cells</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN01">
            <p>Source: Burg G, 2005.4</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>We report the case of a patient with primary cutaneous follicle center lymphoma
(PCFCCL), the most common type of CBCL, which occurs primarily in the skin and whose
clinical manifestations can mimic many other diseases. In our case, the main
differential clinical diagnosis was basal cell carcinoma.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 65-year-old white male patient had had an asymptomatic, smooth-surfaced, erythematous
nodular lesion of 1.2 cm in diameter, with telangiectasia and progressive growth on the
left nasal ala for eight months (<xref ref-type="fig" rid="f01">Figure 1</xref>). The
initial diagnostic hypothesis was basal cell carcinoma. Histopathological examination
revealed a preserved dermis and epidermis with formation of lymphoid follicles.
Lymphocytic cells were identified both in the periphery and center of the follicle
(<xref ref-type="fig" rid="f02">Figure 2</xref>). Immunohistochemistry was positive
for CD20, CD10 and Bcl-6 in cells of the germinal center and negative for Bcl-2, thus
confirming the diagnosis primary cutaneous follicle center lymphoma (<xref ref-type="fig" rid="f03">Figure 3</xref>). Laboratory tests showed normal blood count
and normal Lactate Dehydrogenase (LDH) levels, negative VDRL test, and negative anti-HIV
and anti-HTLV 1 antibodies. CT scans of the chest/abdomen and pelvis showed no signs of
malignancy and the bone marrow biopsy/aspirate showed no abnormalities. The patient
underwent surgical excision of the lesion (<xref ref-type="fig" rid="f04">Figure
4</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Clinical view of the PCFCCL: smooth-surfaced, erythematous nodular lesion of 1.2
cm in diameter, with telangiectasia on the left nasal ala</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0111-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Histopathology of the PCFCCL: preserved dermis and epidermis with formation of
lymphoid follicles. Lymphocytic cells were identified both in the periphery and
center of the follicle. Hematoxylin-eosin, 40X</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0111-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Immunohistochemistry of the PCFCCL: (A) the cytoplasm of B-cells was strongly
positive for CD20. (B) germinal center cells were positive for CD10. (C) germinal
center cells were positive for Bcl-6. (D) germinal center cells were negative for
Bcl-2. Immunohistochemistry, 40X</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0111-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Seventh post-operative day after surgical excision with primary closure of the
lesion on the left nasal ala. Linear incision showing good healing and the
presence of suture stitches</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0111-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>PCFCCL represent 55% of of all CBCL. They have a predilection for males and mainly
affect adults with an average age of 60 years. Clinically, it manifests itself as
solitary or grouped, erythematous to violaceous papules, plaques, nodules or tumors.
They rarely ulcerate or exhibit necrosis. The lesions occur mainly on the head, neck and
trunk. The differential diagnosis includes inflammatory lesions such as acne, epidermal
inclusion cyst, and lymphoid hyperplasia, and cutaneous malignancies such as basal cell
carcinoma.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> In the case presented here, the first diagnostic
hypothesis was basal cell carcinoma. Diagnostic differentiation was carried out by means
of histology, immunohistochemistry and staging tests.</p>
      <p>The five year survival rate is over 95%. Spread to lymph nodes or internal organs is
rare (5%). The recurrence rate is high (about 50%), but there is not a worse prognostic
factor and it is usually confined to skin.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> Histologically, it
presents dermal and subcutaneous proliferation of centrocytes and centroblasts in a
follicular and/or diffuse growth pattern. The tumor cells express B-cell markers such as
CD20, CD79a, CD10, Bcl-6 and negativity for Bcl-2.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> For single lesions, as in the case reported here, the first choice
of treatment is radiotherapy or surgical excision.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>Differentiating between primary and secondary skin involvement, through undiagnosed
nodal or visceral malignancies, is crucial in addressing CBCL, because of the difference
in prognosis and therapeutic options, given that primary and secondary B-cell lymphomas
are clinically and histologically indistinguishable.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup> In the past, it was
believed that CBCL were invariably secondary. In recent years, however, it has been
recognized that CBCL whose primary site is the skin represent a distinct and very
important group of extranodal lymphomas.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article Wanczinski MI, Pinto CAL, Trevisan F, Cunha PR, Grohs LMH.
Primary cutaneous follicle center lymphoma simulating basal-cell carcinoma on the
nasal ala . An Bras Dermatol. 2015;90 (3 Suppl 1):S111-4.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Faculty of Medicine of Jundia&#xED; (FMJ) - Jundia&#xED; (SP),
Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Su&#xE1;rez</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Pulitzer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Querfeld</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Myskowski</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Primary cutaneous B cell lymphomas. Part I. Clinical features,
diagnosis and classification</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2013</year>
          <volume>69</volume>
          <fpage>329.e1</fpage>
          <lpage>329.13</lpage>
          <pub-id pub-id-type="pmid">23957984</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Su&#xE1;rez</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Querfeld</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pulitzer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Myskowski</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Primary cutaneous B cell lymphomas. Part II. Therapy and future
directions</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2013</year>
          <volume>69</volume>
          <fpage>343.e1</fpage>
          <lpage>343.11</lpage>
          <pub-id pub-id-type="pmid">23957985</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Sampaio</surname>
              <given-names>SAP</given-names>
            </name>
            <name>
              <surname>Rivitti</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <chapter-title>Leucemias, Linfomas e Pseudolinfomas</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Sampaio</surname>
              <given-names>SAP</given-names>
            </name>
            <name>
              <surname>Rivitti</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <source>Dermatologia</source>
          <edition>2. ed</edition>
          <publisher-loc>S&#xE3;o Paulo</publisher-loc>
          <publisher-name>Artes M&#xE9;dicas</publisher-name>
          <year>2000</year>
          <fpage>887</fpage>
          <lpage>913</lpage>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kempf</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kazakov</surname>
              <given-names>DV</given-names>
            </name>
            <name>
              <surname>Michaelis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dummer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <chapter-title>WHO/EORTC Classification of Cutaneous Lymphomas</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kempt</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <source>Cutaneous lymphomas</source>
          <publisher-loc>Florida</publisher-loc>
          <publisher-name>Taylor &amp;amp; Francis Group</publisher-name>
          <year>2005</year>
          <fpage>91</fpage>
          <lpage>92</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
